0001453687false00014536872023-08-252023-08-25

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 25, 2023    
 
SELECTA BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
 
Delaware 001-37798 26-1622110
(State or other jurisdiction
of incorporation)
 (Commission
File Number)
 (IRS Employer
Identification No.)
 
65 Grove Street, Watertown, MA 02472
(Address of principal executive offices)(Zip Code)
 
(617) 923-1400
Registrant’s telephone number, including area code
 
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock (Par Value $0.0001)SELBThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 25, 2023, the Board of Directors (the “Board”) of Selecta Biosciences, Inc. (the “Company”) approved a one-time cash bonus payment (each, a “Retention Bonus” and together, the “Retention Bonuses”) to certain of the Company’s executive officers equal to a multiplier of that executive officer's annual base salary for 2023, including Carsten Brunn (2x annual base salary), Blaine Davis (2x annual base salary), Peter Traber (1.5x annual base salary), Takashi Kei Kishimoto (1x annual base salary) and Lloyd Johnston (2x annual base salary), provided that each such executive officer remains employed by the Company in good standing on March 31, 2024. The Retention Bonus payments will be made on the first payroll date following March 31, 2024. In connection with the approval of the Retention Bonuses, the Board delegated authority to the Compensation Committee of the Company (the “Compensation Committee”) to release any individual receiving a Retention Bonus prior to March 31, 2024, at its discretion. In such event, the applicable Retention Bonus shall be paid to such individual employee in connection with any approved separation package. The Compensation Committee, at its discretion, may also elect to accelerate payment of any Retention Bonus or waive any service requirements imposed in connection with any Retention Bonus at any time.





SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 SELECTA BIOSCIENCES, INC.
  
  
Date: September 25, 2023By:/s/ Carsten Brunn, Ph.D.
  Carsten Brunn, Ph.D.
  President and Chief Executive Officer

v3.23.3
Cover Page Document
Aug. 25, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 25, 2023
Entity Registrant Name SELECTA BIOSCIENCES, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-37798
Entity Tax Identification Number 26-1622110
Entity Address, Address Line One 65 Grove Street,
Entity Address, City or Town Watertown,
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code 617
Local Phone Number 923-1400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock (Par Value $0.0001)
Trading Symbol SELB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001453687
Amendment Flag false

Selecta Biosciences (NASDAQ:SELB)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Selecta Biosciences Charts.
Selecta Biosciences (NASDAQ:SELB)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Selecta Biosciences Charts.